Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - aripiprazole, quantity: 2 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; lactose monohydrate; iron oxide yellow; colloidal anhydrous silica; hyprolose; indigo carmine aluminium lake; microcrystalline cellulose - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Canada - Tiếng Anh - Health Canada

neolab inc - esterified estrogens - tablet - 1.25mg - esterified estrogens 1.25mg - estrogens

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 291.2 mg (equivalent: tapentadol, qty 250 mg) - tablet, modified release - excipient ingredients: iron oxide red; iron oxide yellow; microcrystalline cellulose; propylene glycol; macrogol 6000; lactose monohydrate; hypromellose; magnesium stearate; purified talc; iron oxide black; titanium dioxide; colloidal anhydrous silica - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 232.96 mg (equivalent: tapentadol, qty 200 mg) - tablet, modified release - excipient ingredients: iron oxide yellow; hypromellose; magnesium stearate; colloidal anhydrous silica; iron oxide red; lactose monohydrate; titanium dioxide; purified talc; microcrystalline cellulose; macrogol 6000; propylene glycol - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 174.72 mg (equivalent: tapentadol, qty 150 mg) - tablet, modified release - excipient ingredients: propylene glycol; magnesium stearate; iron oxide red; hypromellose; lactose monohydrate; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; macrogol 6000; purified talc; iron oxide yellow - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 116.48 mg (equivalent: tapentadol, qty 100 mg) - tablet, modified release - excipient ingredients: magnesium stearate; microcrystalline cellulose; purified talc; titanium dioxide; macrogol 6000; hypromellose; colloidal anhydrous silica; propylene glycol; iron oxide yellow; lactose monohydrate - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 58.24 mg (equivalent: tapentadol, qty 50 mg) - tablet, modified release - excipient ingredients: titanium dioxide; lactose monohydrate; propylene glycol; hypromellose; purified talc; colloidal anhydrous silica; macrogol 6000; microcrystalline cellulose; magnesium stearate - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - aripiprazole, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; hyprolose; magnesium stearate; microcrystalline cellulose; maize starch - treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - aripiprazole, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; hyprolose; maize starch; magnesium stearate; microcrystalline cellulose; iron oxide red - treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - aripiprazole, quantity: 30 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate; hyprolose; maize starch; iron oxide red - treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.